Innovent Technologies is redefining the landscape of contract machining and manufacturing with precision, efficiency, and adaptability. With a commitment to precision engineering, Innovent provides ...
Hong Kong-listed Innovent Biologics Inc. is considering a licensing partnership to develop a cancer drug that’s showing promise in treating several types of tumor, according to people familiar ...
Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly.
Dr. Kaijie He, Vice President of Innovent, stated: “We aim to tackle drug resistance and enhance treatment outcomes in immunotherapy by developing next-generation bispecific antibodies, multi-specific ...
SAN FRANCISCO and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results